Cyramza (Ramucirumab): Ramucirumab is a fully human monoclonal antibody developed for the treatment of solid tumors and to treat early symptoms of esophagus cancer. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.The most common adverse effects in a study investigating ramucirumab monotherapy were due to treatment for the early symptoms of esophagus cancer.
- high blood pressure (hypertension)
- low levels of sodium in the blood (hyponatremia)
- low white blood cell count (neutropenia)
- intestinal obstruction
- arterial blood clots